Patients with hepatitis C virus+ post-transplant lymphoproliferative disorder (PTLD) appear to experience decreased survival following liver transplant/immunochemotherapy, according to a study involving nearly 1,500 liver transplant recipients. Investigators looked at PTLD incidence at a single institution over a 10-year period ending in 2016. Among the results:
- PTLD developed in 20 patients, an incidence rate of 1.3%.
- HCV caused PTLD in half of those who developed it.
- Diffuse large B-cell lymphoma—the most frequent histologic subtype—occurred in 17 patients; all of those evaluated achieved complete remission.
- HCV+ patients experienced statistically significant decreased survival.
- 6 patients had increased HCV RNA during therapy.
- 4 developed graft failure, 3 of whom died from liver dysfunction.
Alderuccio J, Stefanovic A, Dammrich D, et al. Decreased survival in hepatitis C patients with monomorphic post-transplant lymphoproliferative disorder after liver transplantation treated with frontline immunochemotherapy. [Published online ahead of print December 18, 2017]. Leuk Lymphoma. doi:10.1080/10428194.2017.1413187.